share_log

Chardan Capital Reiterates Buy on Gain Therapeutics, Maintains $6 Price Target

Chardan Capital Reiterates Buy on Gain Therapeutics, Maintains $6 Price Target

Chardan Capital重申買入增益療法,維持6美元的目標股價
Benzinga ·  03/27 04:38

Chardan Capital analyst Keay Nakae reiterates Gain Therapeutics (NASDAQ:GANX) with a Buy and maintains $6 price target.

Chardan Capital分析師Keay Nakae重申Gain Therapeutics(納斯達克股票代碼:GANX)的買入並維持6美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論